Biorce, a healthtech startup based in Barcelona, has raised €5M from Norrsken VC to improve clinical trials through AI. Norrsken VC supports startups that address significant global challenges while building substantial businesses. The funds will primarily support Biorce's U.S. expansion, increase its engineering and sales workforce, and enhance product development. Currently employing 30 people, Biorce continues to seek AI engineers, software developers, and clinical trial specialists. Clinical trials are crucial for new treatments but face delays, with 70 percent starting late and 60 percent incurring high costs.
Biorce is exactly the kind of pioneering company we're here to back. They're combining deep sector expertise with cutting-edge AI to solve what truly matters.
The platform has the potential to radically reduce both the time and cost of bringing new treatments to market, unlocking huge value for pharma and faster access to life-saving therapies for patients.
We have recently established a presence in the United States and are focusing most of our hiring efforts there while continuing to grow our Barcelona office.
Clinical trials are vital for creating new treatments, but they often face chronic delays; about 70 percent of trials start late and nearly 60 percent are expensive.
Collection
[
|
...
]